Items Tagged ‘American Society of Hematology’

December 13th, 2017

Mogamulizumab Superior to Vorinostat in Cutaneous T Cell Lymphoma

By

Results were recently presented at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta from a international comparative clinical trail evaluating mogamulizumab in patients with previously treated cutaneous T-cell lymphoma (CTCL). Precision cancer medicine utilizes molecular diagnostic testing, including DNA sequencing, to identify cancer-driving abnormalities in a cancer’s genome. Once a […]

View full entry

Tags: American Society of Hematology, ASH, Cutaneous T Cell Lymphoma, Mogamulizumab Vorinostat, News, non-hodgkin lymphoma, Non-Hodgkin's Lymphoma, Precision Cancer Medicine, T-Cell Non-Hodgkin's Lymphoma, targeted therapy


December 20th, 2016

5-Year Survival Improved with Early Use of Jakafi® in Myelofibrosis

By

An analysis of 5-year data from two large clinical trials provide conclusive support that treatment with Jakafi® (ruxolitinib) improves long-term survival, compared to other treatment options for patients with myelofibrosis. Perhaps even more importantly, the data suggests that treatment with Jakafi should be used much earlier in the course of a patient’s disease because it […]

View full entry

Tags: 2016, Acute Myeloid Leukemia, American Society of Hematology, ASH, COMFORT-I, COMFORT-II, essential thrombocythemia, jakafi, MF, mpn, myelofibrosis, myeloproliferative neoplasm


December 16th, 2016

Interferon No Better Than Hydroxyurea and Associated with Worse Side Effects in Polycythemia Vera and Essential Thrombocythemia

By

The use of interferon as initial therapy in MPN is associated with worsening side effects the longer it is used for treatment. These results were recently presented at the 2016 annual meeting of the American Society of Hematology. Myeloproliferative neoplasms (MPNs) are a related group of blood cancers. In these disorders, the bone marrow cells […]

View full entry

Tags: 2016, American Society of Hematology, ASH, essential thrombocythemia, ET, hydroxyurea, Interferon, interferon alpha-2a, MPD-RC 112 trial, mpn, myeloproliferative neoplasms, Myeloproliferative Neoplasms MPN